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ABSTRACT
Background. Liver transplant (LT) candidates with hepatocellular carcinoma (HCC) often receive cancer
treatment before transplant. We investigated the impact of
pre-transplant treatment for HCC on the risk of posttransplant recurrence.
Methods. Adult HCC patients with LT at our institution
between 2013 and 2020 were included. The impact of preLT cancer treatments on the cumulative recurrence was
evaluated, using the Gray and Fine-Gray methods adjusted
for confounding factors. Outcomes were considered in two
ways: 1) by pathologically complete response (pCR) status
within patients received pre-LT treatment; and 2) within
patients without pCR, grouped by pre-LT treatment as A)
none; B) one treatment; C) multiple treatments.
Results. The sample included 179 patients, of whom 151
(84%) received pretreatment and 42 (28% of treated)
demonstrated pCR. Overall, 22 (12%) patients experienced
recurrence. The 5-year cumulative post-LT recurrence rate
was significantly lower in patients with pCR than those
without pCR (4.8% vs. 19.2%, P = 0.03). In bivariable
analyses, pCR significantly decreased risk of recurrence.
Among the 137 patients without pCR (viable HCC in the
explant), 28 (20%) had no pretreatment (A), 70 (52%) had
one treatment (B), and 39 (20%) had multiple treatments
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(C). Patients in Group C had higher 5-year recurrence rates
than those in A or B (39.6% vs. 8.2%, 6.5%, P = 0.004 and
P \ 0.001, respectively). In bivariable analyses, multiple
treatments was significantly associated with recurrence.
Conclusions. pCR is a favorable prognostic factor after
LT. When pCR was not achieved by pre-LT treatment, the
number of treatments might be associated with post-LT
oncological prognosis.

Hepatocellular carcinoma (HCC) has a high recurrence
rate after curative-intent hepatectomy.1 Intrahepatic recurrence is the most common presentation, accounting for
more than 70% of cases.2 HCC patients with United Network for Organ Sharing (UNOS) classification T2 disease
(solitary lesion\5.0 cm, within 3 lesions\all 3.0 cm) may
be candidates for liver transplantation (LT), which
decreases risk of recurrence among patients without major
vascular invasion or extrahepatic metastases.3–5 Five-year,
overall survival rates may reach 70-90% in appropriately
selected cases.6 Despite the favorable oncologic outcomes
of LT for HCC, its widespread use as a treatment option is
relatively limited due to donor shortage and disease progression during waitlist time7; to prevent drop-out
secondary to disease progression during waiting time, LT
candidates with HCC often receive treatment, such as
resection, ablation, or chemotherapy.8
According to a recent, multicenter study, patients who
achieved pathological complete response (pCR) after preLT locoregional therapies showed significantly lower rates
of recurrence and superior survival.9 Other single-center
studies suggested that pCR was associated with improved
post-LT outcomes.10–12 However, the impact of these
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treatments on post-LT outcomes in patients who could not
achieve pCR is debatable. We compared the post-LT outcomes between patients with and without pCR and to
assess an impact of the number of pre-LT treatment on
post-LT outcomes.
METHODS
Study Population
Henry Ford Health System (HFHS) is an integrated
tertiary care center in metropolitan Detroit, Michigan.
Study protocols were approved by the HFHS Institutional
Review Board (#15052); requirements for written,
informed consent were waived due to the deidentified and
observational nature of data. Retrospective medical records
data were collected for patients who received a liver
transplant for HCC between January 2013 and December
2019. Adult patients (C18 years) with HCC identified by
pathology in their explants or pre-LT biopsy were eligible
for inclusion. Patients with HCC mixed with cholangiocarcinoma, and those receiving retransplant or combined
transplant with thoracic organs, intestine, and/or pancreas
were excluded. One patient who experienced intraoperative
death was excluded (Supplementary Fig. 1). To assess the
impact of pre-LT treatment on post-LT recurrence in
patients with HCC, two overlapping study samples were
created. The first sample included patients who received
anticancer treatment for HCC before transplant. The second sample included patients who showed viable HCC in
their explants (i.e., patients who did not receive anti-cancer
treatment or failure to achieve pCR).
Covariates
Categorical variables included: recipient sex; etiology of
end-stage liver disease (hepatitis B virus [HBV], hepatitis
C virus [HCV], nonalcoholic steatohepatitis [NASH],
cholestatic disease, alcohol-related liver disease); presence
of severe/moderate grade ascites; grade III/IV
encephalopathy, type of pre-LT treatment (transcatheter
arterial chemoembolization [TACE], Yttrium-90 [Y90],
ablation, liver resection, external radiation therapy, systemic chemotherapy), presence of pCR in explants, tumor
number (single or multiple), vascular invasion, type of liver
transplant (deceased or living donor liver transplantation
[LDLT]), receipt model for end-stage liver disease
(MELD) exception points, HCC criteria (Milan criteria,13
University of California San Francisco (UCSF) criteria,14
up to 7 criteria,15 Japanese 5-5-500 criteria16), and use of
donation after circulatory death (DCD) donor liver graft.

Continuous variables were classified as the following
multilevel categorical variables: recipient serum albumin at
transplant (\2.8 g/dl [33rd percentile], 2.8-3.5 g/dl
[34–65th percentile], and [3.5 g/dl [66th percentile]);
recipient MELD score without exception points at transplant (6–14, 15–29, and C30); maximum AFP from HCC
diagnosis (\200 ng/ml, 200–1000 ng/ml, and [1,000 ng/
ml); AFP at LT (\200 ng/ml, 200–1,000 ng/ml, and[1000
ng/ml); AFP response (low AFP [AFP persistently \200
ng/ml from time of HCC diagnosis]; Responder [maximum
AFP 200-1,000 ng/ml to \200 ng/ml at LT, or maximum
AFP [1,000 ng/ml to \1,000 ng/ml at LT (must be [50%
drop)]; Nonresponder [maximum AFP 200–1000 ng/ml to
[200 ng/ml at LT, or maximum AFP[1,000 ng/ml to AFP
[1,000 ng/ml at LT])17; the number of pretransplant
treatments for HCC (none, one, or multiple); and cold
ischemia time (\6.0 h, 6.0–7.9 h, or C8 h). Additional
multilevel categorical variables included: tumor differentiation (well, moderate, or poor); Karnofsky score at
transplant (10–30%, 40–60%, or 70–100%); and donor
cause of death (trauma, anoxia, cerebrovascular accident
[CVA], or other). Age, body mass index (BMI), tumor size,
and amount of blood loss at transplant were used as continuous variables. All covariates except presence of pCR in
explants, tumor size and number, vascular invasion, and
tumor differentiation were collected before or at LT.
Aim 1: Impact of pCR on Post-LT HCC Recurrence
Among Patients Who had pre-LT Treatment
Patients who received pre-LT treatment for HCC were
classified into two groups: pCR and non-pCR. pCR was
defined as the absence of any viable tumor in their explants
(if patients had multiple tumors, 100% necrosis was confirmed in all tumors). Patient characteristics and
cumulative incidence of recurrence and overall survival
after LT were compared between the two groups. Multivariable analysis was performed to investigate the most
favorable pre-LT treatment method for pCR using logistic
regression. Univariable analyses for risk factors (including
pCR) for recurrence was performed, followed by bivariable
analysis between pCR and other significant risk factors.
Aim 2: Impact of Number of Pre-LT Treatments
and AFP Response on Post-LT Recurrence in Patients
Without pCR
Patients with viable HCC in their explants were classified to three groups according to the number of pre-LT
treatments for HCC: none (group A); one (group B); or
multiple (group C). AFP response was categorized as
above. Patient characteristics, cumulative incidence of
recurrence, and overall survival post-LT were compared
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between each treatment number group. We performed
univariable analyses of risk factors for post-LT recurrence,
including the number of pre-LT treatments for HCC or
AFP response, followed by bivariable analysis between the
number of pre-LT treatments or AFP response and other
significant risk factors.
Statistical Analysis
Patient and donor characteristics were reported by
group. Descriptive statistics for these variables included
median and interquartile range (IQR) for continuous variables and numbers and percentages for categorical
variables. Continuous variables were compared with the
Mann-Whitney U test and categorical variables were
compared using the chi-square test. Logistic regression was
used for the multivariable analysis to identify the optimal
pCR treatment method. Post-transplant patient survival was
evaluated using the Kaplan-Meier method and groups
compared using log-rank tests. Cumulative incidence of
recurrence was evaluated using the cumulative incidence
function and groups compared using the Gray test. The
Fine-Gray method was used to create the univariable and
bivariable models for analysis of recurrence. Patient death
and HCC recurrence were considered as competing risk
events.18 P values \0.05 was considered statistically significant for all analyses. All statistical analyses were
completed using SPSS version 27 (IBM, Chicago, IL) and
R version 3.5.1 (R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Patient Characteristics and Outcomes in the Entire
Cohort
A total of 179 patients were eligible for this study
(Supplementary Fig. 1). Pre-LT treatments included: 28
(16%) none; 92 (51%) one; and 59 (33%) multiple (Supplementary Table 1). There were 233 total treatments
among the 151 pre-LT treated patients (minimum: 1;
maximum: 5). The most common pre-LT treatment was
transcatheter arterial chemoembolization (TACE), which
was administered 118 times (51%); liver resection was
performed only 5 times (2%; Supplementary Table 2). Six
patients had a peak AFP [1,000 ng/ml (3%), and no
patients had an AFP at LT [1,000 ng/ml. Forty-two
patients (24%) achieved pCR.
The 1-, 3-, and 5-year cumulative incidence of post-LT
HCC recurrence were 5.7% (95% confidence interval [CI]
2–9%), 10.0% (95% CI 6–15%), and 12.9% (95% CI
8–18%), respectively (Supplementary Fig. 2a). The 1-, 3-,

and 5-year overall post-LT survival rates were 93.7% (95%
CI 89–96%), 86.1% (95% CI 79–90%), and 78.8% (95%
CI 70–84%) respectively (Supplementary Fig. 2b).
The proportions of patients who showed beyond transplant criteria at initial diagnosis were 35% (Milan criteria),
31% (UCSF criteria), 13% (Up to 7 criteria), and 17% (5-5500 criteria) (Supplementary Table 1). Downstaging rates
(the number of patients who showed within transplant
criteria at LT divided by those of patients who showed
beyond transplant criteria at initial diagnosis were 35%
(Milan criteria), 53% (UCSF criteria), 39% (up to 7 criteria), and 58% (5-5-500 criteria), respectively
(Supplementary Table 3).
Compared with patients who showed within transplant
criteria at both initial diagnosis and LT, the cumulative
incidence of post-LT HCC recurrence was significantly
higher in patients who showed beyond transplant criteria at
both initial diagnosis and LT (P \ 0.001 in each criteria)
(Supplementary Fig. 3). There was no statistical difference
between patients who showed within transplant criteria at
both initial diagnosis and LT and patients who showed
downstaging (P = 0.24 in Milan criteria, P = 0.10 in UCSF
criteria, P = 0.74, and P = 0.22 in 5-5-500 criteria.
Aim 1: Impact of pCR on Post-LT HCC Recurrence
Among Patients Who had pre-LT Treatment
Among 151 patients who received pre-LT treatment for
HCC, 42 demonstrated pCR, and 109 did not (non-pCR). A
larger proportion of the pCR group had serum albumin
levels [3.5 g/dl compared with the non-pCR group (48%
vs. 28%, P = 0.03) and cold ischemia time\6.0 h (91% vs.
72%, P = 0.04; Table 1). In multivariable analysis, the
treatments most strongly associated with pCR were Y90
(odds ratio [OR] 3.60, 95% CI 1.23-10.50, P = 0.01) and
ablation (OR 2.97, 95% CI 1.07-8.19, P = 0.03; Table 2).
Among patients who showed beyond Milan criteria at the
initial diagnosis (n = 62), the number of patients who
received Y90 was 13 and those who showed pCR was 6
(pCR rate was 46.2%) (TACE; 19.5% [8/41], ablation 6.3%
[1/16], radiation 25.0% [1/4], systemic 0% [0/6]; P = 0.06).
Two pCR patients had recurrence. Cumulative incidence
of post-LT recurrence was lower in the pCR group than the
non-pCR groups (1-, 3-, and 5-year: 4.8%, 4.8%, and 4.8%
vs. 9.3%, 15.4%, and 19.2%, respectively, P = 0.03;
Fig. 1a). Overall post-LT survival rates were higher in the
pCR group than the non-pCR group but not significantly
(Fig. 1b). The unadjusted risk of recurrence was significantly lower in the pCR group compared to the non-pCR
group (subdistribution hazard ratio [sHR] 0.22, 95% CI
0.05-0.98, P = 0.04). In bivariable analysis adjusted for
recurrence risk factors identified in univariable analysis,
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TABLE 1 Comparison of characteristics of liver transplant recipients with or without pCR among patients who received pre-LT treatment for
hepatocellular carcinoma
Characteristics

Group

pCR
N = 42
60 [55, 64]

62 [59, 65]

0.14

Male

27 (64)

83 (76)

0.20

Female
Recipient BMI (kg/m ), median [IQR]

15 (36)
27.5 [25.3, 30.8]

26 (24)
28.7 [25.0, 32.4]

0.50

HBV, n (%)

0 (0)

2 (2)

0.92

HCV, n (%)

28 (67)

66 (61)

0.61

NASH, n (%)

4 (10)

21 (19)

0.23

Alcohol, n (%)

12 (29)

28 (26)

0.87

Cholestatic disease, n (%)

1 (2)

2 (2)

1.00

Recipient age (yr), median [IQR]
Recipient gender, n (%)
2

Multiple pre-LT treatments, n (%)

Non-pCR
N = 109

P

20 (48)

39 (36)

0.25

TACE

22 (52)

78 (72)

0.04

Y90

12 (29)

17 (16)

0.11

Ablation

20 (48)

31 (28)

0.04

Liver resection

1 (2)

4 (4)

1.00

Radiation

3 (7)

8 (7)

1.00

Systemic

2 (5)

7 (6)

0.99

LDLT, n (%)

2 (5)

6 (6)

1.00

Exception, n (%)
Albumin (g/dl), n (%)

33 (79)
20 (48)

81 (74)
31 (28)

0.73
0.03

47 (43)

Pre-LT treatment, n (%)

MELD score, n (%)

Karnofsky score (%), n (%)

[3.5
2.8–3.5

17 (41)

\2.8

5 (12)

31 (28)

6-14

27 (64)

62 (57)

15-29

12 (29)

42(39)

[29

3 (7)

5 (5)

70–100

4 (10)

9 (8)

40–60

34 (81)

91 (84)

10–30

4 (10)

9 (8)

0.47

0.93

Severe/moderate ascites, n (%)

6 (14)

14 (13)

Grade III/IV encephalopathy, n (%)

2 (5)

4 (4)

1.00

41 (98)

105 (96)

1.00

AFP at LT (ng/ml), n (%)

Peak AFP (ng/ml), n (%)

AFP response, n (%)

\200
200-1,000

1 (2)

4 (4)

[1000

0 (0)

0 (0)

\200

37 (88)

93 (85)

200-1000
[1000

3 (7)
2 (5)

12 (11)
4 (4)

1.00

0.75

Low AFP

37 (88)

93 (85)

Responder

3 (7)

11 (10)

0.85

Nonresponder

2 (5)

5 (5)

median [IQR]

1000 [800, 1657]

1550 [1000, 3000]

0.01

Recurrence, n (%)

2 (5)

20 (18)

0.06

Death, n (%)

3 (7)

20 (18)

0.14

Donor age (year), median [IQR]

38 [27, 54]

43 [30, 56]

0.28
0.32

Amount of blood loss at LT (ml),

Donor gender, n (%)
Cold ischemia time (hours), n (%)

Male

29 (69)

64 (59)

Female

13 (31)

45 (41)

\ 6.0

38 (91)

78 (72)

6.0–7.9

3 (7)

26 (24)

0.04
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Table 1 (continued)
Characteristics

Group

DCD donor, n (%)
Donor cause of death, n (%)

pCR
N = 42

Non-pCR
N = 109

C 8.0

1 (2)

5 (5)

Trauma

6 (14)
18 (43)

11 (10)
38 (35)

Anoxia

8 (19)

32 (29)

CVA

13 (31)

31 (28)

Others

3 (7)

8 (7)

P

0.65
0.61

Bold denotes statistically significant P values \ 0.05
AFP alpha-fetoprotein; BMI body mass index; CVA cerebrovascular accident; DCD donation after circulatory death; HBV hepatitis B virus; HCC
hepatocellular carcinoma; HCV hepatitis C virus; LDLT living donor liver transplantation; LT liver transplant; MELD model for end-stage liver
disease; NASH nonalcoholic steatohepatitis; pCR pathological complete response; TACE transcatheter arterial chemoembolization; Y90 Yttrium90
Data were summarized by using the median with interquartile range (IQR) for continuous variables and by using percentage for discrete
variables. Continuous variables were analyzed using the Mann-Whitney U test and discrete variables were analyzed using a chi-square test

TABLE 2 Impact of pre-LT treatment for hepatocellular carcinoma
on pCR
OR

95% CI

P

TACE

0.92

0.35–2.42

0.87

Y90

3.60

1.23–10.50

0.01

Liver resection

0.68

0.06–7.68

0.76

Ablation

2.97

1.07–8.19

0.03

Systemic

0.60

0.10–3.36

0.56

Radiation

0.63

0.14–2.82

0.55

Bold denotes statistically significant P values \ 0.05
LT liver transplant; pCR pathological complete response; TACE
transcatheter arterial chemoembolization; Y90 Yttrium-90

pCR patients had a significantly lower risk of recurrence
(Table 3).
Aim 2: Impact of the Number of Pre-LT Treatments
and AFP Response on Post-LT Recurrence in Patients
Without pCR
Of the 137 patients who had viable HCC in their
explants, 28 were as group A (no pre-LT treatments), 70
were group B (1 treatment), and 39 were group C (multiple
treatments). As shown in Table 4, group A patients had the
lowest rate of HCC exception points (4%, 70%, and 82%,
for groups A, B, and C, respectively, P \ 0.001). Group C
had the highest proportion of multiple tumors (39%, 37%,
and 74% for groups A, B, and C, respectively, P = 0.001).
Patients in group C had the highest rate of exceeding up-to7 criteria (4%, 11%, and 26% for groups A, B, and C,
respectively, P = 0.02), and 5-5-500 criteria (0%, 7%, and
18%, for groups A, B, and C, respectively, P = 0.03).

The cumulative incidence of post-LT HCC recurrence
was highest in Group C (1-, 3-, and 5-year: 0%, 3.9%, and
8.2% in group A; 0%, 4.6%, and 6.5% in group B; and
21.1%, 30.5%, and 39.6% in group C, respectively; group
A vs. C, P = 0.004; group B vs. C, P \ 0.001; Fig. 2a).
Overall post-LT survival rates in group C were significantly lower than those in group B (1-, 3-, and 5-year:
97.1%, 92.4%, and 85.3% in group B, 86.5%, 66.4%, and
61.3% in group C, P = 0.002) but similar to group A (P =
0.43; Fig. 2b).
Unadjusted risk of recurrence was significantly higher in
Group C compared to Group A (sHR 6.79, 95% CI
1.61–28.63, P = 0.009). Those in groups A and B were
similar. Bivariable analysis adjusted for recurrence risk
factors identified in the univariable analysis showed that
receipt of multiple treatments (group C) was associated
with significantly higher risk of recurrence with any of
combination of other significant factors (Table 5). Also,
prolonged cold ischemia time (C8.0 h) was significantly
associated with recurrence of HCC compared with cold
ischemia time \6.0 h.
Of the 137 patients who had viable HCC in their
explants, 121 were classified as Low AFP, 12 as Responders, and 4 as Nonresponders. The cumulative incidence of
post-LT recurrence in Nonresponders after pre-LT treatment(s) was significantly higher than in those with Low
AFP or Responders (1-, 3-, and 5-year: 3.4%, 9.9%, and
13.4% [Low AFP]; 8.3%, 8.3%, and 17.6% [Responders];
75.0%, 75.0%, and 75.0% [Nonresponders]; Low AFP vs.
Nonresponders, P \ 0.001; Responders vs. Nonresponders,
P = 0.03; Fig. 2c). In univariable analysis, Nonresponders
showed significantly higher risk for HCC recurrence
compared with Low AFP (sHR 11.22, 95% CI 2.44-51.52,
P = 0.001). Risk of post-LT recurrence in Nonresponder
status was assessed in a bivariable model, which revealed
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(a) Recurrence after LT in pCR and

(b) Patient survival after LT in pCR

Non-pCR group
pCR (n = 42)
Non-pCR (n = 109)

pCR (n = 42)
Non-pCR (n = 109)

100

Overall survival (%)

30

Cumulative recurrence (%)

and Non-pCR group

20

10

95
90
85
80
75

0

70
0

20

10

30

40

50

60

Months from transplant
Number at risk
pCR 42
Non-pCR 109

Year

41
90

36
76

30
57

Recurrence rate (%)
pCR

1-year

33
68

4.8

26
49

15
36

0

10

20

P

Year

40

37
82

33
71

30
61

Overall survival rate (%)
pCR

Non-pCR

1-year

97.6

93.5

Non-pCR
9.3

30

60

26
52

15
36

P

0.06

0.03
3-year

4.8

15.4

3-year

94.9

83.8

5-year

4.8

19.2

5-year

91.9

77.5

FIG. 1 Comparison of post-LT outcome between pCR and non-pCR
groups. a Cumulative recurrence rates after LT in group pCR were
significantly lower than those in group non-pCR (1-, 3-, and 5-year:
4.8%, 4.8%, and 4.8% in patients who achieved pCR; 9.3%, 15.4%,
and 19.2% in non-pCR patients, respectively, P = 0.03). b Overall

50

Months from transplant

Number at risk
pCR 42
41
Non-pCR 109
95

patient survival rates after LT in patients who achieved pCR; there
was no statistically significant difference compared with those
without pCR (1-, 3-, and 5-year: 97.6%, 94.9%, and 91.9% vs.
93.5%, 83.8%, and 77.5%, respectively, P = 0.06)

TABLE 3 Risk factors for HCC recurrence after liver transplantation among patients with pre-LT treatment for hepatocellular carcinoma
Variables

aHR (95% CI)

P

pCR (Ref. non-pCR) aHR (95% CI)

P

Bivariate analysis with pCR for factors associated with recurrence
Recipient gender, male

3.54 (0.88–14.21)

0.07

0.22 (0.05–0.98)

0.04

MELD score C30 (Ref. 6–14)

3.13 (1.04–9.34)

0.04

0.21 (0.04–0.95)

0.04

Multiple treatments (Ref. one treatment)

5.97 (2.43–14.69)

\ 0.001

0.17 (0.04–0.77)

0.02

AFP at LT 200–1000 ng/ml (Ref. \200 ng/ml)

8.65 (1.98–37.65)

0.004

0.21 (0.04–0.95)

0.04

Maximum AFP [1,000 ng/ml (Ref. \200 ng/ml)

4.57 (1.15–18.10)

0.03

0.22 (0.05–0.99)

0.04

0.24 (0.06–0.85)

0.02

AFP nonresponder (Ref. Low AFP)

15.13 (3.95–57.92)

\ 0.001

Bold denotes statistically significant P values \ 0.05
AFP alpha-fetoprotein; aHR adjusted hazard ratio; HCC hepatocellular carcinoma; LT liver transplant; MELD model for end-stage liver disease;
pCR pathological complete response.

that nonresponse was a significant risk factor for recurrence
(Supplementary Table 4).

DISCUSSION
In a sample of 179 HCC patients who underwent liver
transplant, we found that patients who achieved pCR had
significantly lower post-LT HCC recurrence compared to
those without pCR. Patients who could achieve downstaging showed similar post-LT outcomes compared with
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TABLE 4 Comparisons of characteristics of patients according to the number of pre-LT treatment for hepatocellular carcinoma among patients
who showed viable HCC in their explants
Characteristics

Group

Group A
N = 28
61 [56, 63]

62 [58, 65]

64 [60, 67]

0.12

Male

23 (82)

52 (74)

31 (80)

0.65

Female
Recipient BMI (kg/m ), median [IQR]

5 (18)
28.8 [26.9, 33.0]

18 (26)
29.1 [25.6, 32.8]

8 (20)
27.1 [24.5, 31.9]

0.29

HBV, n (%)

1 (4)

1 (1)

1 (3)

0.79

HCV, n (%)

16 (57)

45 (64)

21 (54)

0.53

NASH, n (%)

7 (25)

12 (17)

9 (23)

0.60

Alcohol, n (%)

9 (32)

18 (26)

10 (26)

0.79

Cholestatic disease, n (%)

0 (0)

2 (3)

0 (0)

0.37

Recipient age (yr), median [IQR]
Recipient gender, n (%)
2

Group B
N = 70

Group C
N = 39

P

LDLT, n (%)

2 (7)

4 (6)

2 (5)

Exception, n (%)

1 (4)

49 (70)

32 (82)

\0.001

[ 3.5

4 (14)

17 (24)

14 (36)

0.06

2.8-3.5

12 (43)

36 (51)

11 (28)

\ 2.8

12 (43)

17 (24)

14 (36)

6-14

5 (18)

43 (61)

20 (51)

15-29

16 (57)

23 (33)

18 (46)

[ 29

7 (25)

4 (6)

1 (3)

70-100
40-60

2 (7)
20 (71)

8 (11)
56 (80)

1 (3)
35 (90)

10-30

3 (8)

Albumin (g/dl), n (%)

MELD score, n (%)

Karnofsky score (%), n (%)

0.94

\ 0.001

0.15

6 (21)

6 (9)

Severe/moderate ascites, n (%)

11 (39)

10 (14)

4 (10)

0.005

Grade III/IV encephalopathy, n (%)

6 (21)

3 (4)

1 (3)

0.005

\ 200

28 (100)

68 (97)

37 (95)

0.46

200-1000

0 (0)

2 (3)

2 (5)

[ 1000

0 (0)

0 (0)

0 (0)

\ 200

28 (100)

60 (86)

33 (85)

200-1000

0 (0)

8 (11)

4 (10)

[ 1000

0 (0)

2 (3)

2 (5)

Low AFP

28 (100)

60 (86)

33 (86)

Responder

0 (0)

8 (11)

4 (10)

Nonresponder

0 (0)

2 (3)

2 (5)

median [IQR]

2.1 [1.5, 2.6]

2.4 [1.5, 3.4]

2.2 [1.8, 3.0]

0.48

Multiple tumors, n (%)
Vascular invasion, n (%)

11 (39)
1 (4)

26 (37)
5 (7)

29 (74)
6 (15)

0.001
0.19
0.21

AFP at LT (ng/ml), n (%)

Peak AFP (ng/ml), n (%)

AFP response, n (%)

0.27

0.27

Maximum tumor size (cm),

Differentiation, n(%)

Well

7 (25)

25 (36)

6 (15)

Moderate

19 (68)

40 (57)

28 (72)

Poor

2 (7)

5 (7)

5 (13)

Amount of blood loss at LT (ml),
median [IQR]

1,000 [625, 3,275]

1850 [1000, 3000]

1200 [950, 2,500]

0.52

Beyond Milan criteria, n (%)

5 (18)

20 (29)

16 (41)

0.11

Beyond UCSF criteria, n (%)

3 (11)

12 (17)

12 (31)

0.09

Beyond up to 7 criteria, n (%)

1 (4)

8 (11)

10 (26)

0.02

Beyond 5-5-500 (Japanese) criteria, n (%)

0 (0)

5 (7)

7 (18)

Recurrence, n (%)

2 (7)

5 (7)

13 (33)

Death, n (%)

8 (29)

8 (11)

12 (31)

0.02

Donor age (yr), median [IQR]

35 [28, 48]

43 [30, 55]

44 [28, 56]

0.43

0.03
\ 0.001
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Table 4 (continued)
Characteristics

Group

Group A
N = 28

Group B
N = 70

Group C
N = 39

P

Donor gender, n (%)

Male

19 (68)

40 (57)

25 (64)

0.56

Cold ischemia time (hr), n (%)

Female
\6.0

9 (32)
21 (75)

30 (43)
50 (71)

14 (36)
28 (72)

0.93

6.0-7.9

6 (21)

16 (23)

10 (26)

C8.0

1 (4)

4 (6)

1 (3)

1 (4)

7 (10)

4 (10)

0.55

Trauma

15 (54)

24 (34)

14 (36)

0.56

Anoxia

6 (21)

20 (29)

12 (31)

CVA

4 (14)

21 (30)

10 (26)

Others

3 (11)

5 (7)

3 (8)

DCD donor, n (%)
Donor cause of death, n (%)

Data were summarized by using the median with interquartile range (IQR) for continuous variables and by using percentage for discrete
variables. Continuous variables were analyzed using the Mann Whitney U test and discrete variables were analyzed using a chi-square test
Bold denotes statistically significant P values \ 0.05
AFP alpha-fetoprotein; BMI body mass index; CVA cerebrovascular accident; DCD donation after circulatory death; HBV hepatitis B virus; HCC
hepatocellular carcinoma; HCV hepatitis C virus; LDLT living donor liver transplantation; LT liver transplant; MELD model for end-stage liver
disease; NASH nonalcoholic steatohepatitis; pCR pathological complete response; UCSF University of California San Francisco

those who showed within transplant criteria at both initial
diagnosis and LT. Among patients with pre-LT treatment,
we observed that AFP was associated with risk of recurrence. Nonresponders were more than 11 times more likely
to experience recurrence compared with Low AFP patients.
Change in AFP before and after treatment could be used as
a surrogate marker to predict a risk of post-LT HCC
recurrence. These were consistent with the previous
reports.9,17 In addition, a history of multiple pre-LT treatments without pCR was associated with risk of post-LT
recurrence of HCC.
In our cohort, pCR was associated with a lower risk of
post-LT recurrence. This is consistent with previous
research. DiNorcia et al. analyzed 3,439 patients who
received pre-LT locoregional therapy for HCC; they found
that patients who demonstrated pCR had lower rates of
recurrence compared to without pCR (5 years: 5.8% vs.
16%).9 Our study also showed that the patients who
achieved pCR had significantly lower cumulative recurrence than those without pCR. We found that rates of pCR
were highest with Y90 and ablation. While ablation is a
well-recognized curative therapy,19 the indication of ablation therapy is limited to small, nondiffuse tumors, which
should not be close to major vasculature.20,21 Y90 has been
reported to be useful for patients with unresectable or
recurrent HCC but with fewer adverse events compared
with other interventions.22,23 Salem et al. reported that
patients treated with Y90 had a longer time-to-progression
and fewer adverse events than those who received TACE

for unablatable or unresectable HCC.22 Recently, Somma
et al. reported that complete response rate of 70% after
Y90, according to modified Response Evaluation Criteria
in Solid Tumors (mRECIST).23 There are several reports
about use of Y90 as a bridging or downstaging therapy
prior to LT. One study showed that the downstaging rate
was higher in Y90 than in TACE but that post-LT recurrence was similar,24 whereas another noted that Y90 was
associated with lower risk of post-LT recurrence and with
presence of microvascular invasion (3.6% in Y90, 27% in
TACE).25 According to the largest single-center study
about Y90 prior to LT by Gabr et al., a successful rate of
bridging to transplant was 98% and downstaging rate from
T3 or 4 to T2 was 47%.26 In our study cohort, 32 patients
received Y90. The proportion of patients who had small
tumor (\2 cm) was 25% (n = 8), and the proportion of
patients who had single tumor was 38% (n = 12). The
maximum tumor size was 9.5 cm, and maximum tumor
number was 10. Also, the proportion of patients who
showed pCR was 46.2% among patients who received Y90
and showed beyond Milan criteria at the diagnosis.
Although it did not reach statistical significance, this rate
was higher compared with other modalities. Y90 might be
available even for patients who are not suitable candidates
for ablation, such as patients beyond Milan criteria. Our
results also might support the use of Y90 as an option for
pre-LT tumor control.
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Recurrence after LT according to preLT treatment history

(a)

100

Overall survival (%)

40

Cumulative recurrence (%)

Patient survival after LT according to
pre-LT treatment history

(b)

30

None (Group A: n = 28)
20

One (Group B: n = 70)
Multiple (Group C: n = 39)

10

90

80

70

None (Group A: n = 28)

60

One (Group B: n = 70)
Multiple (Group C: n = 39)

0
50
0

10

20

30

40

50

60

0

Months from transplant
Number at risk
Group A
Group B
Group C

28
70
39

24
65
25

Year

22
58
18

20
53
15

17
47
10

14
40
9

Recurrence rate (%)
Group
A

Group
B

1-year

0

0

21.1

3.9

4.6

30.5

5-year

8.2

6.5

39.6

Group A
Group B
Group C

Year

P

Group
C

3-year

(c)

13
28
8

Group
A vs. C

Group
B vs. C

0.004

<0.001

10

Number at risk
28
24
70
65
39
30

20

30

40

22
59
23

21
54
17

19
48
13

Recurrence rate (%)
Group
A

50

60

15
41
11

13
28
8

Months from transplant

Group
B

P

Group
C

1-year

89.1

97.1

86.5

3-year

81.4

92.4

66.4

5-year

66.8

85.3

61.3

Group
A vs. C

Group
B vs. C

0.43

0.002

Recurrence after LT in patients according to
AFP response to pre-LT treatment

Cumulative recurrence (%)

100

80

Low AFP<200 ng/ml (L) (n = 121)

60

Responders (R) (n = 12)
Nonresponders (N) (n = 4)

40

20

0
0

10

Number at risk
Group A 121
103
Group B
12
10
Group C
4
1

Year

20

30

40

50

60

55
7
1

43
5
1

Months from transplant
88
9
1

78
9
1

65
8
1

Recurrence rate (%)

P

L

R

N

1-year

3.4

8.3

75.0

3-year

9.9

8.3

75.0

5-year

13.4

17.6

75.0

L vs. N

R vs. N

<0.001

0.03

FIG. 2 Comparison of post-LT outcomes among groups A, B, and C.
a Cumulative recurrence rates after LT in group C were significantly
higher than those in group A or B (1-, 3-, and 5-year: 0%, 3.9%, and
8.2% in group A; 0%, 4.6%, and 6.5% in group B; 21.1%, 30.5%, and
39.6% in group C, respectively; group A vs. C, P = 0.004; group B vs.
C, P \ 0.001). b Overall patient survival rates after LT in group C
were significantly lower than those in group B (1-, 3-, and 5-year:
97.1%, 92.4%, and 85.3% in group B, 86.5%, 66.4%, and 61.3% in

group C, respectively; P = 0.002) but similar between groups C and A
(1-, 3-, and 5-year: 89.1%, 81.4%, and 66.8% in Group A, P = 0.43).
c Cumulative recurrence rates after LT in Nonresponders were
significantly higher than those with Low AFP or Responders (1-, 3-,
and 5-year: 3.4%, 9.9%, and 13.4% in Low AFP; 8.3%, 8.3%, and
17.6% in Responders; 75.0%, 75.0%, and 75.0% in Nonresponders,
respectively; Low AFP vs. Nonresponders, P\0.001; Responders vs.
Nonresponders, P = 0.03)
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TABLE 5 Risk for recurrence after liver transplantation among patients who showed viable HCC in their explants
Variables

aHR (95%CI)

P

Multiple (Group C) (Ref. None[Group A]) aHR
(95%CI)

P

Bivariate analysis for the risk of the number of pre-LT treatment for HCC recurrence
MELD score C30 (Ref. 6-14)
AFP at LT 200-1,000 ng/ml (Ref. \200 ng/
ml)
AFP nonresponder (Ref. Low AFP)
Maximum tumor size

0.002

12.09 (2.80–52.16)

12.21 (3.84–38.77) \ 0.001

6.49 (1.96–21.45)

5.34 (1.25–22.85)

12.34 (3.87–39.31) \ 0.001
1.31 (1.10–1.55)

0.002

\ 0.001
0.02

5.28 (1.22–22.69)

0.02

6.22 (1.46–26.46)

0.01

Multiple tumors

2.18 (0.84–5.66)

0.11

5.46 (1.31–22.77)

0.02

Vascular invasion

5.10 (1.69–15.39)

0.003

5.03 (1.22–20.76)

0.02

Beyond Milan criteria

3.40 (1.38–8.36)

0.007

5.43 (1.28–23.05)

0.02

Beyond UCSF criteria

2.44 (0.99–5.99)

0.05

5.92 (1.40–25.04)

0.01

Beyond up to 7 criteria

3.70 (1.43–9.54)

0.006

5.07 (1.17–21.96)

0.03

Beyond 5-5-500 criteria

5.99 (2.05–17.47)

0.001

4.55 (1.03–20.04)

0.04

Cold ischemia time C 8.0 h (Ref. \ 6.0 h)

5.58 (2.06–15.08) \ 0.001

7.34 (2.04–26.34)

0.002

Bold denotes statistically significant P values \ 0.05
AFP alpha-fetoprotein; aHR, adjusted hazard ratio; HCC hepatocellular carcinoma; LT liver transplant; MELD model for end-stage liver disease;
UCSF University of California San Francisco

We also found that a history of multiple pre-LT treatments was significantly associated with posttransplant
recurrence. A U.S. multicenter study of 3,601 patients, who
received bridging locoregional therapy, showed that receipt
of three or more locoregional therapies was associated with
HCC recurrence; need for additional treatments likely
represents more aggressive tumor biology.27 In our study,
the recurrence rate in patients with multiple treatments was
higher than those with one treatment, whereas the recurrence rate in patients without any pre-LT treatment was
similar to those with one treatment. Because patients with
multiple pre-LT treatments were more likely to have more
advanced tumors, we adjusted for other oncological factors
using bivariable models, which confirmed that a history of
multiple treatments was an unfavorable factor for recurrence. When LT patients had viable HCC in the explant
liver even after pre-LT treatment(s), the number of pre-LT
treatment may need to be taken into account for post-LT
monitoring for HCC recurrence, because the risk of HCC
recurrence associated with multiple treatments in this
population was independent of other oncological factors.
Several groups have reported that local HCC recurrence
after treatment exhibit more aggressive tumor behavior
than treatment-naı̈ve HCC.28–31 Recurrence after insufficient ablation for HCC resulted in dedifferentiation or
higher proportion of vascular invasion.28,29 An experimental study showed that sublethal heat treatment
transforms HCC cells to a progenitor-like, highly proliferative cellular phenotype in vitro and in vivo.30 In
addition, a previous study reported that the doubling time

of recurrent lesions after TACE was shorter than that of the
first diagnosed HCC and that the prognosis was worse in
cases with a short doubling time.31 Those findings might
account for the association of multiple pre-LT treatments
and non-pCR with the higher risk of post-LT HCC
recurrence.
In our study, prolonged cold ischemia time was significantly associated with the recurrence of HCC after LT. We
previously reported that cold ischemia time [10 h was
significantly associated with recurrence of HCC after LT.32
Ling et al. also reported a similar result in which cold
ischemia time \ 12 h.33 Although our cutoff value of cold
ischemia time was different from their studies, our result
was consistent with these reports. Experimentally, hypoxia
facilitates cellular growth, adhesion, and angiogenesis.34
Ischemia reperfusion injury also impairs the hepatic
microcirculatory barrier and activates cell invasion and
migration.35 These might lead to the recurrence of HCC.
There are a number of limitations to our study. This is a
retrospective, single-center analysis with a small sample
size. Consequently, we could include only two variables in
our multivariable analysis. Also, it was not possible to
determine whether the administered pre-LT therapy was
intended as downstaging or bridging therapy. Despite these
limitations, this study provides important insights into the
risk stratification for HCC recurrence especially for
appropriate post-LT follow-up.

Multiple Pretransplant Treatments for Patients…

CONCLUSIONS
pCR is associated with lower rates of post-LT recurrence in HCC patients who received pre-LT treatment.
Aggressive downstaging prior to LT should be tried. In
cases without pCR, if the initial diagnosis is advanced
HCC, the indication for transplantation might be carefully
considered. To validate our findings, further studies would
be warranted. In addition, we found that Y90 was the
treatment most likely to be associated with achieving pCR.
Because multiple pre-LT treatments and AFP trend are
strong risk factors for HCC recurrence among patients who
have viable HCC in their explants, these patients should be
monitored carefully after LT.
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